Clinical Research Directory

Inclusion Criteria: * Histologically or pathologically confirmed malignant cholangiocarcinoma. * Patients who have undergone curative surgical resection. * Age between 18 and 75 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Expected survival time \>3 months. * Adequate organ and bone marrow function, including:Absolute neutrophil count ≥1.5 × 10\^9/L,Platelet count ≥75 × 10\^9/L,Hemoglobin ≥90 g/L,Total bilirubin ≤1.5 × upper limit of normal (ULN),AST and ALT ≤2.5 × ULN,Albumin ≥3 g/dL,Serum creatinine ≤1.5 × ULN. * Ability to understand and willingness to sign written informed consent. * For patients of childbearing potential, willingness to use effective contraception during the study and for at least 1 month after the last dose; negative pregnancy test within 72 hours prior to enrollment. Exclusion Criteria: * Prior treatment with immune checkpoint inhibitors or other agents targeting T-cell co-stimulatory or co-inhibitory pathways (e.g., CTLA-4, CD137). * Use of any investigational drug within 4 weeks prior to enrollment. * Active autoimmune disease or history of autoimmune disease (e.g., interstitial lung disease, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, or hypothyroidism requiring hormone replacement). * Known immunodeficiency, including HIV infection, active hepatitis B (HBV DNA \>500 IU/mL), active hepatitis C (HCV RNA above detection limit), or co-infection of HBV and HCV. * Severe infection within 4 weeks prior to first dose or unexplained fever \>38.5°C during screening. * History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. * Uncontrolled psychiatric disorders. * Severe or uncontrolled comorbidities that may interfere with study participation (e.g., unstable angina, myocardial infarction within 6 months, symptomatic arrhythmia, congestive heart failure, uncontrolled diabetes, or uncontrolled infection). * History of other malignancies within the past 5 years, except for non-melanoma skin cancer or carcinoma in situ. * Known hypersensitivity to study drugs or monoclonal antibodies. * Inability or unwillingness to provide informed consent.